Slide 5 of 21
Notes:
Contains some very important points:
Make clear that duration and dose were blinded
Protocol-defined distribution of geno 1, HVT was unequal:
- highly unlikely that 24 wks would be optimal in this population
- FDA request that we test some
- (if required) re-treatment of 48 wks with standard dose RBV offered to all Group A/B relapsers
